Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 27 clinical trials
Featured trial
Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab or Ramucirumab and Pembrolizumab in Pretreated Patients With NSQ NSCLC (CARMEN-LC04)  

Primary Objectives: Doublet Cohort Part 1 (safety run-in): To assess the tolerability and to confirm the recommended dose of tusamitamab ravtansine in combination with ramucirumab in the NSQ NSCLC population. Part 2: To assess the antitumor activity of tusamitamab ravtansine in combination with ramucirumab in the NSQ NSCLC population. Triplet …

  • 0 views
  • 03 Dec, 2024
  • 16 locations
Featured trial
A Study in Advanced/Metastatic Solid Tumors With the Study Medicine (PF-07329640) When Given Alone or In Combination

The purpose of this study is to learn about the safety (the impact of the study drug on the participant's body), effects of the study drug alone or in combination with bevacizumab or sasanlimab, and to find the best dose. This study is seeking participants who have solid tumors that: …

  • 0 views
  • 03 Dec, 2024
  • 4 locations
Featured trial
A study to understand organizational behavor using a cognitive survey  

A study to understand organizational behavor using a cognitive survey

Accepts healthy volunteers
  • 0 views
  • 14 Mar, 2024
  • 1 location
Featured trial
Elective Adhesiolysis vs. a Wait-and-see Policy to Prevent Recurrences After Conservative Treatment of Adhesive Small Bowel Obstruction  

<p>Rationale: Adhesive small bowel obstruction (aSBO) is a frequent surgical emergency, associated with 3-8% hospital mortality and a high risk of recurrence (20% at two years of follow-up). ASBO can be treated conservatively or by emergency surgery. In the absence of bowel ischemia or strangulation, conservative treatment is often preferred, …

  • 0 views
  • 11 Jun, 2025
  • 2 locations
Featured trial
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors

The primary goal of this study is to assess the safety and tolerability of mRNA-4359 administered alone and in combination with pembrolizumab.

  • 0 views
  • 10 Jan, 2025
  • 25 locations
Featured trial
A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer

This study will test the safety of the combination of ramucirumab and lorlatinib. The researchers will test one or two different doses of lorlatinib in combination with ramucirumab to find the drug combination dose that causes few or mild side effects in participants. Once the researchers find this dose, they …

  • 0 views
  • 10 Jan, 2025
  • 6 locations
A randomized, double-blind study to test an oral medicine, Belumosudil, in combination with corticosteroids in participants at least 12 years of age with newly diagnosed chronic graft versus host disease.

This study is looking for individuals at least 12 years of age with newly diagnosed graft versus host disease after cell transplantation.  Chronic graft versus host disease (cGVHD) is an immune-mediated and fibrotic disorder involving many organs, where the transplanted donor cells attack the transplant recipient’s body, after a stem …

  • 0 views
  • 03 Dec, 2024
  • 58 locations
Isatuximab in Combination With Novel Agents in RRMM - Master Protocol

The purpose of this umbrella study is to evaluate isatuximab when combined with novel agents with or without dexamethasone in participants with relapsed or refractory myeloma. Substudy 01 is the control Substudy. Substudies 02, 03, and 06 are controlled experimental substudies. Substudies 04 and 05 are independent experimental substudies.

  • 0 views
  • 03 Jul, 2025
  • 26 locations
Test Trial specifi-crohns  

Test Trial Chrons Disease - Overview

  • 0 views
  • 17 Mar, 2025
  • 2 locations
To Access the Safety and Effects of Intravenous Administration of AMX-818 Alone and in Combination With Pembrolizumab in Adult Participants With Locally Advanced or Metastatic HER2-Expressing Cancers

This first-in-human (FIH) Phase 1 open-label multicenter dose-escalation and dose-expansion study is designed to evaluate the safety, pharmacokinetics, and preliminary activity of AMX-818 as a single agent and in combination with pembrolizumab in participants with HER2+ tumors across multiple tumor types. The study will be conducted in four parts: Part …

Accepts healthy volunteers
  • 0 views
  • 03 Dec, 2024
  • 10 locations